A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.
PHASE1CompletedINTERVENTIONAL
Enrollment
14
Participants
Timeline
Start Date
September 30, 2002
Study Completion Date
July 31, 2003
Conditions
Tuberculosis
Interventions
BIOLOGICAL
MVA85A (Tuberculosis vaccine)
Trial Locations (1)
OX3 7LJ
University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Oxford
All Listed Sponsors
lead
University of Oxford
OTHER
NCT00423566 - A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers. | Biotech Hunter | Biotech Hunter